Wang Long-Sheng, Chen Shao-Jun, Zhang Jun-Feng, Liu Meng-Nan, Zheng Jun-Hua, Yao Xu-Dong
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, 200072, China.
BMC Urol. 2017 May 30;17(1):38. doi: 10.1186/s12894-017-0221-7.
Renal cell carcinoma (RCC) is one of the most common types of cancer in urological system worldwide. Recently, the anticancer role of Glucosamine has been studied in many types of cancer. The aim of this study was to investigate the effects of Glucosamine on RCC.
The effects of Glucosamine on RCC cell proliferation and apoptosis were investigated by MTT assay and Annexin V-FITC Apoptosis assay, respectively in vitro. Cell cycle was detected by flow cytometry after treatment with Glucosamine. Protein levels of several cell cycle associated markers were examined by Western Blot.
Our data showed that Glucosamine significantly inhibited the proliferation of renal cancer 786-O and Caki-1 cells in a dose-dependent manner. Besides, Glucosamine treatment resulted in cell cycle arrest at G0/G1 phase in both cell lines. Meanwhile, the expression of several regulators that contribute to G1/S phased transition, such as Cyclin D1, CDK4 and CDK6, were significantly down-regulated with the up-regulation of cell cycle inhibitors, p21 and p53, after treatment with glucosamine. However, the apoptosis rate of RCC cells was down-regulated when treatment with Glucosamine at 1 mM and 5 mM, while up-regulated at 10 mM.
Our findings indicated that Glucosamine inhibited the proliferation of RCC cells by promoting cell cycle arrest at G0/G1 phase, but not promoting apoptosis. The present results suggested that Glucosamine might be a potential therapeutic agent in RCC treatment in the future.
肾细胞癌(RCC)是全球泌尿系统中最常见的癌症类型之一。近年来,氨基葡萄糖在多种癌症中的抗癌作用已得到研究。本研究的目的是探讨氨基葡萄糖对肾细胞癌的影响。
分别通过MTT法和Annexin V-FITC凋亡法体外研究氨基葡萄糖对肾细胞癌细胞增殖和凋亡的影响。用氨基葡萄糖处理后,通过流式细胞术检测细胞周期。通过蛋白质免疫印迹法检测几种细胞周期相关标志物的蛋白质水平。
我们的数据表明,氨基葡萄糖以剂量依赖性方式显著抑制肾癌786-O和Caki-1细胞的增殖。此外,氨基葡萄糖处理导致两种细胞系的细胞周期停滞在G0/G1期。同时,在用氨基葡萄糖处理后,几种有助于G1/S期转变的调节因子,如细胞周期蛋白D1、细胞周期蛋白依赖性激酶4(CDK4)和细胞周期蛋白依赖性激酶6(CDK6)的表达显著下调,而细胞周期抑制剂p21和p53上调。然而,当用1 mM和5 mM的氨基葡萄糖处理时,肾癌细胞的凋亡率下调,而在10 mM时上调。
我们的研究结果表明,氨基葡萄糖通过促进细胞周期停滞在G0/G1期来抑制肾癌细胞的增殖,而不是促进细胞凋亡。目前的结果表明,氨基葡萄糖可能是未来肾细胞癌治疗中的一种潜在治疗药物。